Concord Biotech Limited

NSE CONCORDBIO.NS

Concord Biotech Limited Debt to Equity Ratio for the year ending March 31, 2024: 0.01

Concord Biotech Limited Debt to Equity Ratio is 0.01 for the year ending March 31, 2024, a -73.92% change year over year. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.
  • Concord Biotech Limited Debt to Equity Ratio for the year ending March 31, 2023 was 0.02, a -56.83% change year over year.
  • Concord Biotech Limited Debt to Equity Ratio for the year ending March 31, 2022 was 0.06, a -36.59% change year over year.
  • Concord Biotech Limited Debt to Equity Ratio for the year ending March 31, 2021 was 0.09, a 13.70% change year over year.
  • Concord Biotech Limited Debt to Equity Ratio for the year ending March 31, 2020 was 0.08.
Key data
Date Debt to Equity Ratio Debt to Income Ratio Debt to Tangible Net Worth Ratio Dividend Coverage Ratio
Market news
SV Wall Street
NSE: CONCORDBIO.NS

Concord Biotech Limited

CEO Mr. Ankur Vaid
IPO Date Aug. 18, 2023
Location India
Headquarters 16th Floor, B-Wing
Employees 1,377
Sector Health Care
Industries
Pharmaceuticals Biotechnology
Description

Concord Biotech Limited, a biopharma company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in India and internationally. It provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. The company also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus for immunosuppressants therapeutic segment; temsirolimus, everolimus, romidepsin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment; mupirocin, mupirocin calcium, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, and micafungin sodium for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. In addition, it provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.

StockViz Staff

February 6, 2025

Any question? Send us an email